Information for US Healthcare Professionals
Focused on delivering therapies for cancer and autoimmune disease
The CAR is designed to have a “fast-off” kinetic which mimics physiological T cell receptor interactions. Clinical trials of obe-cel have demonstrated that this enhanced kinetic profile can result in increased T cell persistence leading to potentially high levels of durable remissions and low levels of cytokine release syndrome and other immunotoxicities.
Autolus are applying extensive cell programming capability to develop product candidates across hematological malignancies, solid tumors and autoimmune disease.